Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2– Metastatic Breast Cancer — What the Latest Data Really Tell Us

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Hope S. Rugo, MD, FASCO; Fabrice André, MD, PhD; Nadia Harbeck, MD; and Heather McArthur, MD, MPH; discuss updates from the SERENA-6, evERA, PREcoopERA, and TRAK-ER trials of oral selective estrogen receptor degraders (SERDS) in patients with hormone receptor–positive/HER2-negative (HR+/HER2–) early, advanced, and metastatic breast cancer (MBC). These results were presented at European Society for Molecular Oncology (ESMO) Breast 2026.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify approved and emerging oral SERDs for the management of HR+/HER2– breast cancer.
• Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD-based treatment strategies for patients with HR+/HER2– MBC.
• Integrate clinical trial data, real-world evidence, and patient- and disease-specific factors to inform personalized treatment decisions for patients with HR+/HER2– MBC.

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Stemline Therapeutics, Inc.

Chair:

Hope S. Rugo, MD, FASCO

Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF

Disclosures: Consulting or Advisory Role: BioNTech, Bristol Myers Squibb, Helsinn, Napo; Grant/Research Funding (to prior institution, UCSF): Ambryx, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche/Genentech, Gilead Sciences, Lilly, Merck & Co, Novartis Pharmaceuticals, Pfizer, Stemline Therapeutics; Grant/Research Funding (to current institution, COH): Bicycle Therapeutics, F. Hoffmann-La Roche/Genentech, Merck & Co, Stemline Therapeutics

Faculty:

Fabrice André, MD, PhD

Head of Research
Professor of Medicine, Department of Medical Oncology
Université Paris Saclay
Gustave Roussy
Villejuif, France

Disclosures: Honorarium: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Relay Therapeutics; Research Grants or Advisory Boards (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Lilly, Novartis, Pfizer, Relay Therapeutics, Roche

Nadia Harbeck, MD, PhD

Director, Breast Center
Department of Obstetrics and Gynecology
LMU University Hospital
Munich, Germany

Disclosures: Consulting/Advisory Role: Daiichi Sankyo, IQVIA, Novartis, Pfizer, Roche/Genentech; Speakers Bureau: Amgen, AstraZeneca, Daiichi Sankyo, Exact Sciences, Lilly, Menarini-Stemline, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Viatris, Zuellig Pharma; Research Funding (Institutional): AstraZeneca, Lilly, MSD, Novartis, Pfizer, Roche/Genentech; Stock/Ownership: WSG (Women’s Cancer Study Group)

Heather McArthur, MD, MPH

Professor of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, TX

Disclosures: Consultant: Amgen, Arvinas, AstraZeneca, Bristol Myers Squibb, Calithera, Celgene, Daiichi Sankyo, Genentech/Roche, Immunomedics, Lilly, Merck, OBI Pharma, Peregrine, Pfizer, Puma, Seattle Genetics, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, TapImmune; Grant/Research Support: Bristol Myers Squibb, BTG, MedImmune/AstraZeneca, Merck

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including further expert discussion about these trials of oral SERDs for patients with HR+/HER2– breast cancer, go to https://www.gotoper.com/courses/oncology-town-hall-updates-from-berlin-oral-serds-in-hrher2-metastatic-breast-cancerwhat-the-latest-data-really-tell-us-vlv3.

Release Date

June 15, 2026

Expiration Date

June 15, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.